Novartis has forged an alliance with a Saudi Arabian manufacturer to help it expand its vaccines business in the Middle East and North African (MENA) region and neighbouring countries.
The Arab Company for Pharmaceutical Products (Arabio) is constructing a manufacturing facility in Makkah Almokarramah, with technical assistance from Novartis' Vaccines and Diagnostics divisions, which should start operating in early 2011.
AbbVie will partner with Arabio to manufacture Humira and other drugs in Saudi Arabia. -- Courtesy of AbbVie.
As growth has slowed in some emerging markets, Western drugmakers are looking to second- and third-tier emerging markets to gain momentum. The Middle East has become the new hot spot for pharma, and AbbVie ($ABBV) has found its way there.